Celgene Corporation (NASDAQ:CELG) Sellers Strengthened By 12.79% Their Shorts

Celgene Corporation (NASDAQ:CELG) Corporate Logo

Big Money Sentiment decreased to 0.64 in Q4 2018. It has change of 0.29, from 2018Q3’s 0.93. The ratio is negative due to Celgene Corporation positioning: 108 sold and 463 reduced. 106 funds took positions and 262 increased positions. Investors holded 468.90 million in 2018Q3 but now own 491.33 million shares or 4.78% more.
Nordea Mngmt Ab has 0.02% invested in Celgene Corporation (NASDAQ:CELG) for 107,238 shs. Umb Bancshares N A Mo invested in 0.02% or 11,486 shs. Advisory Net Ltd accumulated 25,502 shs or 0.14% of the stock. Usa Portformulas accumulated 18 shs. Haverford Trust holds 0.01% or 5,473 shs in its capital. Bessemer Gru Inc holds 0% or 9,807 shs in its capital. Mufg Americas Holdings stated it has 101,937 shs. Fjarde Ap owns 164,240 shs or 0.18% of their US capital. Cobblestone Advsr Ltd accumulated 13,018 shs. Nomura Asset Mngmt Ltd has 0.26% invested in Celgene Corporation (NASDAQ:CELG) for 362,630 shs. Seizert Capital Prtn Limited Liability Corporation reported 354,502 shs. State Of New Jersey Common Pension Fund D reported 915,353 shs stake. Tcw Gru holds 0.28% or 417,465 shs. The Texas-based Texas Permanent School Fund has invested 0.16% in Celgene Corporation (NASDAQ:CELG). Blackhill Capital has 0.34% invested in Celgene Corporation (NASDAQ:CELG).

Celgene Corporation registered $2.05 million net activity with 0 buys and 1 sale since February 7, 2019.

It was reported an increase on Celgene Corporation (NASDAQ:CELG)’s short interest with 12.79%. FINRA published short interest of CELG’s total 17.11 million shares. The up change of 12.79% from 15.17 million shares was reported. With Average volume 9.36 million, CELG’s previous position will take 2 days to recover. Float short on Celgene Corporation is 2.45%.

The stock increased 1.62% or $1.41 during the last trading session, hitting $88.71.Celgene Corporation has volume of 9.35M shares. Since March 14, 2018 CELG has declined 1.66% and is downtrending. CELG underperformed by 6.03% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The firm is worth $62.31 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.16.1 is the P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

In total 9 analysts cover Celgene (NASDAQ:CELG). “Buy” rating has 3, “Sell” are 0, while 6 are “Hold”. 33% are bullish. 14 are the (NASDAQ:CELG)’s analyst reports since October 1, 2018 according to StockzIntelligence Inc. On Wednesday, December 19 the company was maintained by Morgan Stanley. The company rating was maintained by Wells Fargo on Friday, January 4. The company rating was maintained by Robert W. Baird on Tuesday, March 12. On Monday, December 17 the rating was maintained by Citigroup with “Neutral”. In Friday, February 1 report Jefferies downgraded the stock to “Hold” rating. The company rating was upgraded by Robert W. Baird on Friday, January 4. On Friday, January 4 Goldman Sachs upgraded Celgene Corporation (NASDAQ:CELG) to “Neutral” rating. In Thursday, February 28 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Friday, December 21 the company was reinitiated by BTIG Research. On Thursday, February 28 the stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Robert W. Baird.

For more Celgene Corporation (NASDAQ:CELG) news brought out briefly go to: Nasdaq.com, Globenewswire.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Friday’s Vital Data: Square, Southwest Airlines and Celgene – Nasdaq” brought out on March 01, 2019, “New Research Coverage Highlights Cisco, Mattel, Celgene, Vanda Pharmaceuticals, NuStar Energy, and Aon plc — Consolidated Revenues, Company Growth, and Expectations for 2019 – GlobeNewswire” on February 27, 2019, “Regeneron/Sanofi’s Dupixent Gets FDA Nod for Label Expansion – Nasdaq” with a publish date: March 12, 2019, “Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News – Nasdaq” and the last “Celgene (CELG) Gains But Lags Market: What You Should Know – Nasdaq” with publication date: March 11, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.